Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 6,641

Document Document Title
WO/2006/106440A1
The present invention relates to new macrolide compounds represented by the general structure I, wherein M is a macrolide, P is a photo-affinity group bearing subunit containing biotin, and L is a linking molecule, and to their pharmaceu...  
WO2006087238A9
A process for the conversion of 6-11 bridged bicyclic ketolide or erythromycin oximes to 6-11 bridged bicyclic ketolides or erythromycins comprises reacting a 6-11 bridged macrolide with a deoximating agent, preferably an oxidative deoxi...  
WO2006086103A3
The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar...  
WO/2006/100330A2
The invention relates to novel polyenes having formula (I), wherein: R1 represents alkyl, C1-C3; and R2 represents a functional group selected from CH3- or CONH2- (methyl or primary amide). The aforementioned polyenes have a biocide acti...  
WO/2006/100413A2
The invention relates to novel compounds derived from 5-thioxylose, preferably 5-thioxylopyranose-type derivatives, and to the preparation method thereof and the use of same as an active principle in medicaments which are intended, for e...  
WO/2006/098761A2
The invention provides purified 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment...  
WO2005058236A8
The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in diagnosis and therapy.  
WO/2006/098413A1
Disclosed is a process for producing a glucopyranosyloxypyrazole derivative which is useful as a prophylactic or therapeutic agent for a disease induced by hyperglycemia, such as diabetes, a diabetes complication and obesity. A process f...  
WO/2006/094456A1
The invention provides an extract of Styrax Linn, which comprises from 40 to 98 % by weight of total benzofurans of Styrax Linn. It also provides the preparation and uses of such extract. The extract according to the invention has the ch...  
WO2006065743A3
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions...  
WO/2006/092081A1
The invention provides structures of active compounds isolated from medicinal herbal of Euphorbia Lunulata and the use thereof. These compounds possess insulin- or IL-10-like activity, wherein the structures of compounds (1), (2), (4), (...  
WO/2006/092739A1
The present invention relates (a) to new compounds represented by Formula (I) wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, each D repres...  
WO/2006/092049A1
The invention comprises compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions containing the compounds or prodrugs of the compounds. The invention also comprises animal models and m...  
WO/2006/090935A1
Discloses is an acerola fruit-derived pectin in the form of a complex with aceronidin that is a novel polyphenolic compound or a hydrolysate of the pectin. The pectin can be used as an antioxidative agent or the active ingredient for a s...  
WO/2006/087997A1
[PROBLEMS] To provide a compound having SGLT1 and/or SGLT2 inhibiting potency that can be used as a preventive or therapeutic agent for diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complication, obesity, etc...  
WO/2006/087238A1
A process for the conversion of 6-11 bridged bicyclic ketolide or erythromycin oximes to 6-11 bridged bicyclic ketolides or erythromycins comprises reacting a 6-11 bridged macrolide with a deoximating agent, preferably an oxidative deoxi...  
WO/2006/088256A1
A process for producing a glycoside compound having a trans configuration selective for the 2-position hydroxy group from (a) a furanose compound or pyranose compound and (b) an alcohol compound, characterized in that use is made of a fu...  
WO/2006/087644A2
The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4" position, to their pharmaceutically acce...  
WO/2006/085228A2
Novel 9a-N'-substituted-carbamoyl- and tMocarbamoyl-aminoalkyl-9a-aza-9-deoxo- 9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro- 9a-homoerythromycin A compounds having antimalarial activity are claimed. More ...  
WO/2006/084410A1
The present invention relates to new antibiotic macrolide compounds of the general formula (I): with improved activity, to medicaments comprising such antibiotics, and to the use of such antibiotics for the treatment of infectious diseas...  
WO2006063039A3
The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof (I), which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions ...  
WO2006046112A3
The present invention provides ketolide derivatives, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treating or preventing conditions caused by or contributed to by gram positive, gram negative...  
WO2006065721A3
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions compr...  
WO/2006/080954A1
The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gra...  
WO/2006/078032A1
A novel compound having an anti-penicillin resistant pneumococci potency; and an anti-penicillin resistant pneumococci agent containing the compound as an active ingredient. There is provided an anti-penicillin resistant pneumococci agen...  
WO/2006/077501A2
The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides lacking cladinose sugar substituted at the C-3 position, to th...  
WO/2006/078450A1
The present invention discloses compounds of formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof, which exhibit antibacterial properties. The present invention further relates to pharmaceutical compos...  
WO/2006/074962A2
This invention relates to a novel class of antibiotic agents, more specifically to macrolides comprising an oxazolidinone structure, their preparation, pharmaceutical compositions containing them, their use and methods of treatment using...  
WO2006039263A3
The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) (II)which exhibit antibacterial properties. The present invention further relates to pharmaceutical co...  
WO/2006/075255A2
The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a...  
WO/2006/073172A1
A compound represented by the following general formula (I) [wherein R1, R2, and R3 each independently represents hydrogen or alkylcarbonyl; and R4 and R5 each independently represents hydrogen, optionally substituted alkyl, optionally s...  
WO/2006/072334A2
The invention relates to a method for producing thiophene glycoside derivatives of general formula (I), wherein: Y represents hydrogen or alkyl; R1 represents alkyl, whereby hydrogen can be substituted by fluorine or aryl, and aryl can a...  
WO/2006/070883A1
A novel composition of &agr -glycosylisoquercitrin, which has excellent in vivo absorbability and, as a result, shows excellent anti-oxidizing activity in vivo; and a method of preparing the composition. The composition is a quercetin gl...  
WO/2006/067985A1
A polyphenol glycoside derived from acerola. It has a bonding mode which has not been known. Also provided are uses of the glycoside. The glycoside is the compound represented by the formula (I). The uses are an antioxidant, glucosidase ...  
WO/2006/067925A1
Means for remedying the hepatic function of human being and other mammals to normal conditions. There is provided a hepatic function remedial agent comprising &agr -glucosylhesperidin as an active ingredient, and further provided usages ...  
WO/2006/067589A1
Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Formula (I). Also disclosed are methods of preparing the compounds, intermediates...  
WO/2006/068102A1
A compound having the formula (1): can be produced with efficiency by using a compound represented by the formula (2): wherein R represents a protected hydroxyl group or a group represented by the formula (3): where R1 represents an alky...  
WO/2006/064914A1
This invention provides a novel compound having irreversible inhibitory activity against neuraminidase, and a therapeutic agent and a detecting agent for neuraminidase-related diseases. Specifically, there are provided a compound of form...  
WO/2006/065721A2
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions compr...  
WO/2006/065743A2
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions...  
WO/2006/063039A2
The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof (I), which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions ...  
WO2006025051A3
The present invention provides a process of preparing a crystalline azithromycin monohydrate. The process involves dissolving azithromycin in a solution containing ethanol, adding the dissolved azithromycin into water to precipitate the ...  
WO2005002497A3
A novel group of aminoglycosides which share some structural features of currently available aminoglycosides with regard to the backbone, while also having significant structural differences. The similarity enables these aminoglycosides ...  
WO2006024405A3
A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, n is 0, 1 or 2, R1 represents, for instance, a C1-C12alkyl group, R2 represents, for instance, R15 gro...  
WO/2006/050943A1
A compound of formula (I) For use as antibacterial agents, compositions containing same, processes for their preparation and their use in therapy.  
WO/2006/050941A1
A compound of formula (I) compositions comprising same, processes for their preparation and use of said compounds, particularly in the treatment of microbial infections.  
WO/2006/050940A1
A compound of formula (I) compositions comprising same, processes for their preparation and use of said compounds, particularly in the treatment of microbial infections.  
WO/2006/050942A1
Compounds of formula (I) or pharmaceutically acceptable derivatives thereof having antimicrobial activity are disclosed, as are processes for their preparation, compositions containing them and their use in medicine.  
WO/2006/049983A2
Modified fusion proteins of transferring and therapeutic proteins or peptides including, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exh...  
WO/2006/045831A1
The present invention describes natamycin comprising needle shaped crystals.  

Matches 651 - 700 out of 6,641